南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停

MG53 可抑制 IRF7 的表达,从而重编程巨噬细胞,促进胰腺导管腺癌患者的抗肿瘤免疫反应。

MG53 suppresses IRF7 to reprogram macrophages and promote antitumor immunity in pancreatic ductal adenocarcinoma

Yumeng Pei, Meng Fang, Fan Zhang, Danyang Zhao, Yini Li, Jinyan Huang, Xingmei Liang, Rui-Ping Xiao, Tingbo Liang, Hong-Kun Wu

Journal:Cell Reports

IF:7.7

DOI:10.1016/j.celrep.2026.118000

PMID:42747965

Published:2026-09-16

research field:植物生物学分子遗传学胁迫生理学生物化学

Abstract

In pancreatic ductal adenocarcinoma (PDAC), the desmoplastic stroma and immunosuppressive tumor microenvironment (TME) present barriers to immunotherapy. Here, we show that MG53 (TRIM72) is a critical regulator of macrophage fate and anti-tumor immunity; its myeloid-specific depletion accelerates PDAC progression by locking macrophages into a suppressive state, whereas its restoration dismantles the immunosuppressive TME. Mechanistically, MG53 binds the Irf7 locus to suppress the pro-tumorigenic myeloid program, and concomitant IRF7 deletion reverses the phenotype of MG53-deficient models. Clinically, an MG53-low/IRF7-high TAM signature correlates with reduced survival across gastrointestinal malignancies, particularly within PDAC cohorts. Using a macrophage-tropic mRNA-LNP platform to restore MG53 expression in vivo , thereby suppressing tumor growth and enhancing antitumor immune activity in PDAC. Our findings demonstrate that MG53 functions as a myeloid checkpoint regulator and suggest mRNA-based reprogramming as a potential strategy to address therapeutic resistance in PDAC.

本文使用的Yeasen产品

购物车
客服
转染试用